Skip to main content
. 2016 Feb 25;310(9):G716–G725. doi: 10.1152/ajpgi.00273.2015

Fig. 3.

Fig. 3.

Blocking VEGFR2 kinase activity increases the incidence and severity of NEC. DF pups or those subjected to the experimental NEC protocol were injected (ip) with 20 mg/kg of SU5416 (A–C and F) or 1 mg/kg of Ki8751 (D and E) or vehicle control daily. Representative photographic images (top) and histological pictures (bottom) from each group (SU5416 experiments) are shown in A. Scale bar = 100 µm. NEC histological scores are shown in B (SU5416) and D (Ki8751). Pup survival curves are shown in C (SU5416) and E (Ki8751). B, n = 14 in DF, 15 in SU5416 alone, 32 in NEC and 29 in NEC+SU5416 group; C, n = 20 in DF, 19 in SU5416 alone, 38 in each of NEC and NEC+SU5416 group; D, n = 16 in DF, 12 in SU5416 alone, 31 in NEC and 35 in NEC+SU5416 group; E, n = 16 in DF, 13 in SU5416 alone, 38 in NEC and 44 in NEC+SU5416 group. ***P < 0.001. ****P < 0.0001. These data were the combined results of 2 to 3 separated experiments. F: intestinal permeability was measured by serum FITC-dextran (FD4) concentration 4 h following enteral administration of 800 mg/kg of FD4 in DF (n = 22), SU5416 (n = 11), NEC (n = 14), and NEC + SU5416 pups (n = 14). Data represent 3 independent experiments combined. *P < 0.05, **P < 0.005, ****P < 0.0001.